Mizuho Securities analyst Uy Ear has maintained their bullish stance on ARQT stock, giving a Buy rating on November 11.Don't Miss our Black ...

The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...

ZORYVE cream 0.15% is the first once-daily, Food and Drug Administration (FDA)-approved topical treatment for mild to moderate atopic dermatitisZORYVE, a next-generation topical phosphodiesterase-4 ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Organon is a strong investment opportunity with a high yield, diversified portfolio, steady performance, and transformative ...

DelveInsight's Dermatological Drugs Market Insights report provides the current and forecast market analysis, individual ...

and atopic dermatitis, providing physicians and their patients multiple forms of ZORYVE cream and ZORYVE foam to address ...

THIS YEAR saw the 33rd European Academy of Dermatology and Venereology (EADV) Congress that, for the third time in its history, was ...

Third quarter net product revenues for ZORYVE® (roflumilast) franchise of $44.8M, with $22.0M for ZORYVE cream 0.3%, $20.3M for ZORYVE topical ...

Podiatrists and dermatologists explain the benefits of applying a foot cream. Here, shop the 12 best foot creams for dry feet ...

The FDA has extended the review period for the sNDA for tapinarof cream, 1% in the treatment of atopic dermatitis.